Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of Intranasal CHF6467 in Healthy Adults
NCT07163182Phase 1Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CHF6467 (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Adverse Events and Adverse Drug Reactions up to 85 days, Vital Signs (HR, BT, SBP, DBP) and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
CHF6467
Beyond the preview
Go deeper on NCT07163182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163182.